CANC - ETF AI Analysis
Top Page
Tema Oncology ETF (CANC)
Rating:59Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The fund has delivered strong gains so far this year and in recent months, showing solid momentum.
High-Quality Healthcare Leaders
Many top holdings are well-known global drug makers and oncology specialists that have shown steady to strong performance, supporting the ETF’s returns.
Focused Oncology Exposure
The ETF’s heavy focus on oncology and health care gives investors targeted access to a specialized area of the medical sector that has been performing well.
Negative Factors
High Expense Ratio
The fund’s fees are relatively high for an ETF, which can eat into long-term returns compared with lower-cost options.
Sector Concentration Risk
With almost all assets in health care and oncology, the ETF is heavily exposed to setbacks in this single sector.
Limited Geographic Diversification
The portfolio is dominated by U.S. companies, offering little exposure to other regions and reducing the benefits of global diversification.
CANC vs. SPDR S&P 500 ETF (SPY)
AUM196.47M
RegionGlobal
Expense Ratio0.75%
Beta0.78
IssuerTema
Inception DateAug 15, 2023
Dividend Yield0.05%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume27,014
30 Day Avg. Volume30,489
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
56.04Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering58
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CANC Summary
The Tema Oncology ETF (CANC) is a health care fund focused on companies working on cancer treatments, mainly in the pharma, biotech, and life sciences areas. It doesn’t track a traditional index, but instead selects firms leading in oncology research and drug development. Well-known holdings include Eli Lilly and Johnson & Johnson, alongside smaller, more specialized biotech names. Someone might invest in this ETF to seek long-term growth from advances in cancer therapies and to get diversified exposure across many oncology companies. A key risk is that biotech and drug stocks can be very volatile and may rise or fall sharply with trial results and news.
How much will it cost me?The Tema Oncology ETF has an expense ratio of 0.75%, which means you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on a specialized niche in the health care sector that requires expert research and selection of companies.
What would affect this ETF?The Tema Oncology ETF could benefit from advancements in cancer research and increased global demand for innovative treatments, as well as strong performance from top holdings like Eli Lilly and Roche, which are leaders in oncology. However, it may face challenges from regulatory hurdles, high development costs in the biotech sector, and potential economic downturns that could impact funding for healthcare innovation.
CANC Top 10 Holdings
CANC is essentially a bet on cancer drugs, with heavyweight names like Eli Lilly, Novartis, and Merck providing the steady backbone of the portfolio. These big pharma players have been rising over the past few months, helping to drive the fund, while Johnson & Johnson and Bristol-Myers Squibb add more stable, blue-chip support. On the riskier side, smaller biotech names such as Revolution Medicines and Cogent Biosciences are more volatile and have been mixed to lagging, occasionally dragging on returns. Overall, it’s a globally focused, oncology-heavy fund leaning on established drug makers with a dash of high-risk innovation.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Revolution Medicines | 6.19% | $12.15M | $40.85B | 411.96% | 52 Neutral | |
| Cogent Biosciences | 5.55% | $10.90M | $7.07B | 241.49% | 37 Underperform | |
| Eli Lilly & Co | 5.16% | $10.14M | $1.09T | 50.70% | 72 Outperform | |
| Roche Holding | 4.62% | $9.08M | $348.82B | 40.76% | 74 Outperform | |
| Novartis AG | 4.11% | $8.08M | CHF232.08B | 34.41% | 80 Outperform | |
| AbbVie | 3.76% | $7.38M | $454.79B | 28.54% | 66 Neutral | |
| Bristol-Myers Squibb | 3.64% | $7.16M | $132.45B | 47.66% | 78 Outperform | |
| Merck & Company | 3.58% | $7.04M | $320.56B | 64.21% | 80 Outperform | |
| Johnson & Johnson | 3.08% | $6.04M | $616.50B | 53.20% | 78 Outperform | |
| Immunome | 2.85% | $5.59M | $2.61B | 114.92% | 63 Neutral |
CANC Technical Analysis
Neutral
―
Price Trends
39.37
Positive
38.30
Positive
36.48
Positive
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CANC, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 41.19, equal to the 50-day MA of 39.37, and equal to the 200-day MA of 36.48, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CANC.
CANC Peer Comparison
Comparison Results
Performance Comparison
CANC
Tema Oncology ETF
40.60
14.30
54.37%
AVRE
Avantis Real Estate ETF
―
―
―
ARKX
ARK Space Exploration & Innovation ETF
―
―
―
VOLT
Tema Electrification ETF
―
―
―
EIPX
FT Energy Income Partners Strategy ETF
―
―
―
VGSR
Vert Global Sustainable Real Estate ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents